Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
Blood Cancer Journal|August 16, 2022
γ-secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiationHailin Chen, Tengteng Yu, Liang Lin, et al.
Annals of Hematology|December 4, 2023
Immunophenotypic profile defines cytogenetic stability and unveils distinct prognoses in patients with newly-diagnosed multiple myeloma (NDMM)Lihui Shi, Wenqiang Yan, Jingyu Xu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 7, 2025
Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II StudyWenjie Xiong, Yuting Yan, Tingyu Wang, et al.
Haematologica|May 29, 2025
Improving predictive accuracy in multiple myeloma using a plasma cell profile derived from single-cell RNA sequencingLanting Liu, Hao Sun, Fangshuo Feng, et al.
Haematologica|August 3, 2023
Minor clone of del(17p) provides a reservoir for relapse in multiple myelomaJian Cui, Rui Lv, Tengteng Yu, et al.
Blood Advances|September 8, 2020
The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical modelsShih-Feng Cho, Liang Lin, Lijie Xing, et al.
Therapeutic Advances in Medical Oncology|January 22, 2024
Longitudinal genetically detectable minimal residual disease by fluorescence <i>in situ</i> hybridization confers a poor prognosis in myelomaJian Cui, Tengteng Yu, Rui Lv, et al.
Leukemia|July 8, 2020
Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myelomaLiang Lin, Shih-Feng Cho, Lijie Xing, et al.
Leukemia|April 12, 2024
Fluorescence in situ hybridization reveals the evolutionary biology of minor clone of gain/amp(1q) in multiple myelomaJian Cui, Yuntong Liu, Rui Lv, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2021
BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 ExpressionLijie Xing, Su Wang, Jiye Liu, et al.
Pageof 3